Kim Kardashian finds herself in yet another debacle stemming from a social media post. While this incident may not be surprising, as the wife of Kanye West has always been a tabloid favorite ever since her face first appeared on TV, the agency expressing dismay over the "Keeping Up With The Kardashians" star makes the issue unique. Reports reveal that Kim Kardashian is currently battling the Food and Drug Association (FDA).
Raving over the positive effects of Diclegis, a product created by Duschenay, Inc., Kim Kardashian took to social media to share the advantages of the said drug. Telling her fans that Diclegis is a completely safe drug to take even for pregnant women like herself, the FDA found her claims unfounded and requested her to delete the social media post. Apart from contacting Kim Kardashian over the issue, the FDA also ordered the company itself, Diclegis, to send a written explanation on how they intend to guarantee that such incident will not happen again. The Instagram post of the "Keeping Up With The Kardashians" star had been taken down since then.
In a screen grabbed photo taken by Forbes, Kim Kardashian could be seen posing beside a bottle of Diclegis. According to the caption accompanying the picture, the "Keeping Up With The Kardashians" star shared that Diclegis helped her get over the nausea and vomiting of pregnancy (NVP), otherwise known as "morning sickness." Since taking the said drug, Kim Kardashian claimed that she had been feeling better and more relaxed. Mere days following the announcement of her pregnancy, the wife of Kanye West had been very vocal about her struggles involving morning sickness. Hence, the discovery that Diclegis actually worked for her thrilled the reality star.
Apart from raving over the effects of the drug, Kim Kardashian also went on to assure her fans and followers that there is no recorded possibility that Diclegis could pose any "risk to the baby." Unsurprisingly, this claim alarmed the FDA especially since the "Keeping Up With The Kardashians" star has thousands of followers in social media. Officials from the agency felt threatened that Kim Kardashian might have caused a "misbranding" of the drug.
In a letter sent by the FDA to Eric Gervais, the executive vice president of Duschenay, Inc., the agency disclosed that Kim Kardashian's social media post "is false or misleading in that it presents efficacy claims for DICLEGIS." Furthermore, FDA wrote that the post "fails to communicate any risk information associated with its (Diclegis) use and it omits material facts." The agency further wrote, "Thus, the social media post misbrands DICLEGIS within the meaning of the Federal Food, Drug, and Cosmetic Act (FD&C Act) and makes its distribution violative."
At the moment, Kim Kardashian has yet to respond to the letter. As for Gervais, sources reveal that the company is in the process of formulating a reply to the FDA.
